Mutations and ectopic FAT1 cadherin expression are implicated in a broad spectrum of diseases ranging from developmental disorders to cancer. The regulation of FAT1 and its downstream signalling pathways remain incompletely understood. We hypothesized that identification of additional proteins interacting with the FAT1 cytoplasmic tail would further delineate its regulation and function. A yeast two-hybrid library screen carried out against the juxtamembrane region of the cytoplasmic tail of FAT1 identified the E3 ubiquitin-protein ligase SH3RF1 as the most frequently recovered protein-binding partner. Ablating SH3RF1 using siRNA increased cellular FAT1 protein levels and stabilized expression at the cell surface, while overexpression of SH3RF1 reduced FAT1 levels. We conclude that SH3RF1 acts as a negative post-translational regulator of FAT1 levels.
Members of the Fat cadherin family are conserved from flies to vertebrates, with two members in Drosophila, ft and ft2 and four in humans, FAT1, FAT2, FAT3 and FAT4. All Fat genes encode large transmembrane receptors producing protein products of 500-600 kDa [1] . In humans, FAT1 was the first member of Fat cadherin family cloned [2] and as such, has been the most extensively studied. Early work using Fat1 knockout mice revealed a role in kidney development and a low penetrance of neurological and ophthalmological abnormalities [3] . Subsequent whole exome sequencing and homozygosity mapping in humans established that human FAT1 mutations are also involved in glomerular nephropathy [4] . Similarly, defined single nucleotide polymorphisms of FAT1 are linked to bipolar disorder [5] as well as autism [6] thereby establishing the relevance of FAT1 function to the homeostasis of these organ systems.
In addition to its role in developmental disorders, FAT1 has also been investigated in the context of cancer, in part due to early work classifying Drosophila ft as a tumour suppressor gene [7] . FAT1 was later found not to be the true orthologue of ft, but nevertheless a number of reports have shown loss, repression and inactivation of FAT1 occurs in certain cancers [8, 9] . In contrast, a number of cancer types display Abbreviations IGLL1, immunoglobulin lambda locus; NC, negative control; NOXA1, NADPH oxidase activator 1; qPCR, quantitative real-time PCR; SH3RF1, SH3 domain containing ring finger 1; SORBS2, sorbin and SH3 domain containing 2; TRAF4, TNF receptor-associated factor 4. overexpression of FAT1 compared to their normal cell counterparts including acute leukaemia [10] , melanoma [11] and breast cancer [12] . Reconciling these apparent differences and its role in development will require a better contextual understanding of Fat1-regulated signalling pathways (for a review see [1] ).
To this end, lessons from Drosophila have indicated that ft acts as an upstream receptor involved in controlling cell growth through the Hippo signalling pathway [13] [14] [15] [16] , and also lies upstream of the planar cell polarity pathway [17] [18] [19] [20] . Vertebrate Fat1 is also linked to cell migration where it localizes to lamellopodia [21] and engages the actin cytoskeletal network through interaction with Ena/VASP proteins [22] . FAT1 can also regulate the Hippo pathway in neuronal differentiation [23] and Wnt-signalling by binding b-catenin [9] . Of note, high levels of FAT1 protects against TRAIL-induced apoptosis [24] and more recently cytoplasmic tail fragments of the Fat cadherins play an unexpected role controlling mitochondrial function [25] [26] [27] . Collectively these reports highlight the importance of the Fat1 cadherin, and in particular, the cytoplasmic tail as a central hub for activating downstream signalling pathways.
We therefore hypothesized that the discovery of additional novel interacting partners of the FAT1 cytoplasmic tail would allow for further dissection of the signalling functions of FAT1 in both known and unknown cellular contexts. Herein, we report a novel interaction between the FAT1 cytoplasmic tail and SH3RF1 (also known as POSH) and provide clear evidence that SH3RF1 serves to modulate the cellular levels of FAT1.
Materials and methods

Antibodies, vectors and siRNA
Antibodies against SH3RF1 (H00057630; Abnova, Taipei City, Taiwan), V5 (Invitrogen, Carlsbad, CA, USA), GAPDH and PP2A-Ca/b (ID6) (Santa Cruz, Dallas, TX, USA) with in-house anti-FAT1 mAb and pAb used as previously described [11] . Gateway vectors and siRNA duplexes were purchased from Invitrogen and ShanghaiGenePharma (Zhangjiang Hi-Tech Park, Shanghai, China) respectively.
Cell lines and Western blotting
Cell culture methods, preparation of whole cell lysates using NDE lysis buffer and Western blotting were as previously described [11] . Tris-Acetate Gels (NuPAGEÒ; Thermo Fisher Scientific, Scoresby, Vic., Australia) were used to resolve endogenous FAT1 in samples while Bis-Tris gels were employed for other analyses. Rabbit pAbs directed against the C terminus of FAT1 were used for all immunoblotting experiments. Where indicated, bands were quantitated by densitometry using MULTIGAUGE v3.0 software (Fujifilm, Tokyo, Japan).
Coimmunoprecipitation
COS cells were transiently transfected with the pCS2+_FAT1 vector encoding the cytoplasmic domain (aa4203-4588) and pDEST40-SH3RF1 constructs using LipofectAMINE2000 (Thermo Fisher Scientific). Cells were lysed with IP buffer (50 mM Tris-HCl pH8.0, 200 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM DTT) and IP carried out as described [11] . For endogenous coimmunoprecipitation in MDA-MB-231 cells, lysates were prepared using cadherin lysis buffer [1% NP40, 1% Triton X-100, 10 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM CaCl 2 ] before immunoprecipitation with a cocktail of anti-FAT1 mAb (NTD and CTD; Fig. 3A ) as previously described [11] .
Yeast two-hybrid screen
The FAT1 (aa4210-4280) and FAT1 (aa4497-4588) 'bait' sequences were amplified by PCR with high fidelity, proofreading DNA Polymerase (KOD Hot Start; EMD Millipore, Temecula, CA, USA) using gene-specific primers (Integrated DNA Technologies, Coralville, IA, USA) to add attB1 and attB2 sequence tags (Table S1 ) to opposing ends of the bait sequence. Yeast two-hybrid screening against a breast cancer cDNA library was performed as described [28] .
In vitro transcription and translation and GSTpulldown assay
The TNTÒ T7 Quick coupled Rabbit Reticulocyte Transcription/Translation System (Promega, Madison, WI, USA) was used to label the FAT1 sequence (amino acids 4210-4280) with [
35 S]-methionine. Full-length SH3RF1 was amplified from cDNA with a set of primers designed according to the human SH3RF1 cDNA sequence deposited in the GenBank TM /EBI Data Bank (accession number GI: 89142742). SH3RF1 deletion mutants, DRING SH3RF1, (aa 1-11, 54-888), DRING SH3RF1 N TERM (aa1-11, 54-444) and DRING SH3RF1 C-TERM (aa 1-11, 260-888) were cloned into pDEST TM 40 plasmid using the GatewayÒ system (Invitrogen). cells were generated by spinfection and GFP-expressing cells sorted using FACS Aria II flow cytometer (BD Australia, North Ryde, NSW, Australia) until > 90% GFP positive.
siRNA transfection, and inhibition of protein translation and proteasome Transient knockdown of SH3RF1 was carried out using pooled siRNA duplexes (Table S2) . Cells were transfected with pooled SH3RF1 siRNA (#451, #455, #2107) or Neg Ctrl siRNA (with 150 pmol total siRNA: 50 pmol of each SH3RF1 or 150 pmol Neg Ctrl siRNA) using RNAi max (Invitrogen) as per manufacturer's instructions. Cycloheximide and MG132 were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia), Lactacystin was purchased from Enzo Life Sciences (Farmingdale, NY, USA). Cycloheximide (0.1 mM) was used to inhibit protein translation. MG132 (50 lM) and Lactacystin (10 lM) were added to cells 2 h prior to cell lysis.
Quantitative real-time PCR
Quantitative real-time PCR (qPCR) was carried out as described [10] . Briefly, total RNA was isolated using the Illustra RNA minispin kit (GE Healthcare Australia, Parramatta, NSW, Australia), quantitated using a Biophotometer [Eppendorf South Pacific (Macquarie Park, NSW, Australia)] and validated using a 2100 Bioanalyser (Agilent Technologies, Mulgrave, Vic., Australia) with RIN > 9 for all samples. cDNA synthesis was carried out with 500 ng total RNA using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Australia, Dee Why, NSW, Australia) with random hexamers. Reverse transcription was carried out as follows: 10 min at 29°C, 60 min at 48°C, then 5 min at 85°C. Each qPCR reaction contained the following: 5 lL cDNA reaction carried out using the Applied Biosystems 7500 realtime PCR instrument (Foster City, CA, USA) using the following steps: Stage 1: 2 min at 50°C, Stage 2: 10 min at 95°C, Stage 3: 40 cycles of 15 s at 95°C followed by 1 min at 60°C. FAT1 gene expression was normalized to the geometric mean of the reference genes (RPS18, NM_022551.2) and b-glucuronidase (GUSB, NM_000181.3) with the relative gene expression calculated using the 2 ÀDDCt method. Primer sequences are found within Table S3 .
Results
Yeast two-hybrid screening identifies novel FAT1-interacting partners
A yeast two-hybrid screen was undertaken to identify novel proteins interacting with the FAT1 cytoplasmic tail. To improve the possibility of identifying entirely novel interactions, two FAT1 'bait' constructs were designed that corresponded to the FAT1 juxta membrane (aa4210-4280) and carboxyl-terminal (aa4497-4588) regions respectively. The latter bait proved to be auto-activating in yeast and was omitted from the library screen (data not shown; Fig. 1A ). Applying the juxta-membrane bait of FAT1 to three independent library screens identified a total of 13 'prey' clones including SH3RF1, TRAF4, NOXA1, MT-ND1, SORBS2 and IGLL1 (Table 1) . Of these candidates SH3RF1 was the most frequent 'prey' identified with a total of five independent cDNA clones recovered. The SH3RF1-FAT1 interaction was then further validated through second pass screening using a re-derived 'prey' against the FAT1 4210-4280 'bait' and an unrelated 'bait', p53 as a control (Fig. 1B) . Together these data provided strong evidence of a bona fide SH3RF1-FAT1 in the context of the yeast two-hybrid system.
The two N-terminal SH3 domains of SH3RF1 interact with FAT1
The primary structure of the SH3RF1 protein consists of an N-terminal E3 ubiquitin-ligase RING domain followed by four SH3 domains ( Fig. 2A) . In silico analysis of the FAT1 cytoplasmic tail identified a class II SH3 (PxxPxR) binding motif and moreover, the in silico analysis predicted the first two SH3 domains of SH3RF1 are primarily involved in this interaction (Table 2 ). To test whether the SH3 domains of SH3RF1 were responsible for the interaction with FAT1, we utilized domain-deletion constructs of SH3RF1 in GST-pulldown assays. We confirmed that GST-FAT1 4210-4280 specifically bound full-length SH3RF1 in the assay and while the RING domain was dispensable for FAT1 binding, the N-terminal SH3 domains of SH3RF1 were absolutely required ( Fig. 2A) . Furthermore, the requirement for the Nterminal SH3 domains of SH3RF1 in the FAT1 interaction was confirmed using COS cells transiently cotransfected with epitope-tagged SH3RF1 truncation mutants (V5-SH3RF1 1-11,54-888 or V5-SH3RF1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] ) together with a FAT1 intracellular fragment (ICF encompassing aa4203-4588; Fig. 2B ). Finally, the interaction between FAT1 and SH3RF1 was confirmed in situ using MDA-MB-231 where reciprocal coimmunoprecipitation was observed between endogenous FAT1 and SH3RF1 proteins (Fig. 2C ).
SH3RF1 regulates total and cell surface FAT1 protein levels
Collectively these results provide compelling evidence that SH3RF1 is a novel binding partner of FAT1. We therefore considered the functional consequences of this interaction. The presence of the RING domain in SH3RF1 demarks it as an E3 ubiquitin-protein ligase [30] . Indeed this activity has been demonstrated where SH3RF1 has been found to selectively mediate the ubiquitination and proteosomal-dependent degradation of target proteins [31] [32] [33] . This proposed that SH3RF1 could function to regulate FAT1 protein turnover. To test this we determined the impact of manipulating SH3RF1 levels on the expression of FAT1. We first identified that the MDA-MB-231 breast cancer cell line expressed high levels of both FAT1 and SH3RF1. As previously determined for melanoma cells, FAT1 occurs in MDA-MB-231 cells both as full length (p500) and S1-processed (heterodimeric p430/ p85) forms that can be distinguished using domainspecific antibodies (Fig. 3A) [11, 34] . Subjecting the MDA-MB-231 cells to siRNA-mediated knockdown of SH3RF1 resulted in loss of SH3RF1 with a significant upregulation of FAT1 protein levels (Fig. 3B) . This upregulation also led to a significant~2.6-fold increase in cell surface expression of FAT1 as determined by cell surface biotinylation experiments. Here, the amount of cell surface (biotinylated) FAT1 protein was significantly increased after SH3RF1 knockdown with no concomitant change in processing of full length to the heterodimeric form of FAT1 (Fig. 3C) . These results indicate that SH3RF1 can regulate total FAT1 levels including cell surface expression but does not regulate S1-cleavage of FAT1.
Reciprocal experiments were then conducted where SH3RF1 was transfected into the MDA-MB-231 cells. Recombinant expression of epitope-tagged SH3RF1 resulted in a reduction in FAT1 protein levels bỹ 30% (Fig. 3D ). While this represents only a moderate decrease it is entirely consistent with the increase in recombinant SH3RF1 over endogenous levels. Indeed high-level expression of recombinant SH3RF1 could not be achieved and we attribute this to SH3RF1 being able to regulate its own half-life [35] . This notion was supported by experiments using an SH3RF1 construct lacking the RING domain (DRING-SH3RF1; Fig. 3E ). In comparison to full-length SH3RF1, high-level expression of DRING-SH3RF1 could readily be achieved (Fig. 3E) . Moreover, consistent with experiments undertaken in the MDA-MB-231 cells (Fig. 3D ), FAT1 expression levels were again reduced by 30% after transfection of fulllength SH3RF1. However, overexpression of DRING-SH3RF1 did not significantly alter FAT1 levels ( Fig. 3E) , showing that the RING domain of SH3RF1 is required to regulate FAT1 levels.
SH3RF1 does not influence the rate of FAT1 protein decay
As a logical extension of this work we next analysed the effects of SH3RF1 on the stability of the FAT1 protein.
To establish a baseline for this assay, we employed the cycloheximide chase assay to determine the half-life of the FAT1 protein. Unexpectedly, the half-life of FAT1 in MDA-MB-231 cells was found to be~2 h with only 20% of original levels remaining after 8 h (Fig. 4A) . To confirm this, the experiment was repeated in HEK293 where the half-life of FAT1 protein appeared even less than observed for MDA-MB-231 cells (Fig. 4A) . In contrast, parallel blotting experiments with SH3RF1 showed it to be comparably long lived with relatively little diminishment of protein levels across the same time frame (Fig. 4A ). Given that SH3RF1 is a known E3 ubiquitinprotein ligase and that manipulation of SH3RF1 can impact the levels of FAT1, it could be predicted that the half-life of FAT1 would be influenced by the levels of SH3RF1. To determine this, both MDA-MB-231 cells and HEK293 were pretreated with SH3RF1 siRNA for 48 h before conducting a 'chase' assay with the protein synthesis inhibitor cycloheximide. Consistent with prior experiments, baseline levels of FAT1 protein increased in both lines (~1.6-2 fold increase) after SH3RF1 levels were depleted using siRNA (Fig. 4B) . Treatment with cycloheximide for 2 h resulted in a reduction in FAT1 protein levels in both negative control (NC) siRNA and SH3RF1 siRNA-treated cells. Notably, while the baseline levels of FAT1 protein are different for NC and SH3RF1 siRNA treatments, the relative rate of decay was not significantly altered. To ascertain if SH3RF1 levels affected the transcription and/or stability of FAT1 mRNA we undertook qPCR analyses (Fig. 4C) . After 24 h after siRNA depletion of SH3RF1 there was no significant increase in FAT1 mRNA in HEK293 cells although there was a small increase observed in MDA-MB-231 cells after depletion of SH3RF1. However, given the~2-3-fold increase in FAT1 protein levels observed after SH3RF1 depletion these data suggest that the major regulatory mechanism(s) involved are post-transcriptional in nature.
Further experiments in HEK293 treated with MG132 and lactacystin demonstrated that these agents increased FAT1 protein levels, indicating the involvement of the proteasome in FAT1 degradation. However, FAT1 levels still diminished after cycloheximide treatment in the presence of either proteasomal inhibitor, likely indicating that nonproteasomal mechanisms are also involved in the half-life of the FAT1 protein (Fig. 4D ).
Discussion
In this report, we sought to identify and functionally validate novel interacting partners of the FAT1 cytoplasmic tail. Screening of the juxta-membrane region against a breast cancer cDNA library identified six novel binding partners including SH3RF1 that was further investigated in detail. Notably, other FAT1-interacting proteins were NADH dehydrogenase subunit 1 (MT-ND1), a key component of the mitochondrial respiratory chain and NADPH oxidase activator 1 (NOXA1), a component of the NADPH oxidase complex that generates ROS. Significantly, during the preparation of this manuscript, it was shown that fragments of the Fat1 cytoplasmic tail do translocate and directly regulate mitochondrial function [25, 26] . Furthermore, it was also recently shown that SORBS2 (ArgBP2) and SORBS1 (CAP/ponsin) also interact with the FAT1 cytoplasmic tail [36] providing independent evidence that these are bona fide protein-protein interactions. Moreover, it is notable that SORBS2 is suspected to be pathogenic factor in facioscapulohumeral muscular dystrophy [37] , a disease also associated with compromised FAT1 expression in muscle cells [38] . Of the remaining binding partners identified, only immunoglobulin lambda and TRAF4 remain to be investigated in detail, but given the stringent nature of our screen we anticipate this work to yield interesting results.
The most frequent interaction was between FAT1 and SH3RF1 and this was validated in vitro showing that binding to FAT1 involved the N-terminal SH3 domains of SH3RF1, most likely through a class II SH3 (PxxPxR)-binding motif located within the juxtamembrane region of FAT1. SH3RF1 (also known as POSH) is a multifunctional protein composed of four SH3 domains and a single RING (Really Interesting New Gene) domain at the N terminus. The majority of research understanding the function SH3RF1 has been within the central nervous system where it can regulate neuronal cell migration by localizing activated Rac1 and F-actin assembly [39] and induce axon outgrowth and increase neuronal process length Lactacystin for 2 h increases FAT1 levels but addition of cycloheximide for the second hour of the experiment showed that FAT1 is still subject to degradation when the proteasome is inhibited. [40, 41] . SH3RF1 overexpression can also induce apoptosis in neuronal cells by regulating the JNK pathway [35] . However, our SH3RF1 overexpression experiments in MDA-MB-231 did not lead to apoptosis and therefore suggests different roles for SH3RF1 in different murine and human cellular settings. Indeed, some reports have indicated that high SH3RF1 levels can be protective with knockdown of SH3RF1-sensitizing prostate cancer cell lines in TRAIL-induced apoptosis [42] and human RASF cells to Fas-mediated apoptosis [43] . SH3RF1 can also regulate its own half-life in a RING-dependent manner via ubiquitination [35] . Indeed, RING domain is the hallmark of E3 ubiquitin-ligases [30] and several ubiquitination substrates for SH3RF1 have been identified. SH3RF1 can increase the levels of level of Herp at the endoplasmic reticulum through ubiquitination and thereby regulate calcium homeostasis [32] . Similarly, SH3RF1 ubiquitination activity aids virion release by modulating the activity and location of Gag [44] and ALG2-interacting protein X (ALIX) [45] . SH3RF1-mediated ubiquitination has also been demonstrated to play a functional role in the cell surface expression of receptors including ROMK1, a component of ROMK potassium channels [33] and STIM1, a synaptic membrane protein expressed by hippocampal neurons [46] . Given these precedents we therefore hypothesized that FAT1 protein levels could also be regulated by SH3RF1.
Downregulation of SH3RF1 by siRNA caused a significant increase in the level FAT1 protein in breast cancer cells and HEK293 cells concomitant with an increase in cell surface expression. Conversely, overexpression of SH3RF1 led to a decrease in FAT1 protein, albeit to a lesser extent than the effects observed with reciprocal SH3RF1 depletion. However, given the difficulty encountered in achieving high-level expression of SH3RF1, the reciprocal changes observed are consistent with the notion that SH3RF1 regulates cellular levels of FAT1. However, unlike the exemplary reports where SH3RF1 regulated the translocation of ROMKI [33] and STIM1 [46] to or from the plasma membrane, SH3RF1 impacted the total cellular pool of FAT1. Our experiments also establish that the RING domain of SH3RF1 is necessary to modulate FAT1 protein levels implying that SH3RF1 ubiquitin-ligase activity is involved.
Having established that SH3RF1 could regulate FAT1 protein levels we then investigated the rate of protein decay and found quite unexpectedly that FAT1 has a very short half-life of less than 2 h. Previous studies of E-cadherin, a dynamic component of adherens junctions, have a half-life between 5 and 10 h [47] . Considering the core protein mass of FAT1 at~500 kDa, five times the size of E-cadherin, the < 2 h half-life of FAT1 is remarkable. The SH3RF1-mediated ubiquitination of ROMK1 channels involves the ubiquitin-proteasome system [33] and we therefore investigated how SH3RF1 influenced the half-life of FAT1. Depletion of SH3RF1 did not alter the rate of FAT1 protein decay, an observation that held for both cell lines tested. These data argue against a simplified role for SH3RF1 being the only protein involved in the ubiquitin-mediated decay of FAT1 through either proteasomal and/or nonproteasomal (e.g. lysosomal) mechanisms. Rather there are likely to be more complex processes at play. For example, it has been shown for E-cadherin that the E3-ubiquitin-ligase Hakai binds to it transmembrane proximal region where it can promote either endocytosis/recycling or alternatively destruction [48, 49] . Taken together, the short half-life and the potential multiplex role in the regulation of FAT1 protein levels has significant implications for understanding the variety of FAT1 signalling functions necessary for tissue homeostasis. In conclusion, we have demonstrated that SH3RF1 and FAT1 interact in vivo with functional assays, providing clear evidence that SH3RF1 serves to modulate cellular levels of FAT1. These findings further illustrate that the functional significance of protein-protein interactions is often context dependent and this report will aid our understanding on the role FAT1 plays in a diverse range of pathologies. 
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